RenalProTM Prevents Acute Kidney Injury (AKI) at Multiple Clinical Settings
RenalPro,* an FDA designated breakthrough device technology, autonomously bundles fluid management and therapeutic systems that elegantly integrate into the clinical workflow.
The system is unique in its ability to respond to minute fluctuations in urine output while automatically adjusting the administration of IV fluids in milliliter increments. The patient is kept hemodynamically stable, preventing over- or under-hydration.
*RenalPro is branded as RenalGuard outside of the US
The system is unique in its ability to respond to minute fluctuations in urine output while automatically adjusting the administration of IV fluids in milliliter increments. The patient is kept hemodynamically stable, preventing over- or under-hydration.
*RenalPro is branded as RenalGuard outside of the US
The Burden of AKI
With about 3.1 million cases of AKI resulting in about 285,000 deaths in the US alone, AKI prevention is a huge unmet need. It increases hospital costs and burdens doctors, patients, and the healthcare system. Because of its severity, AKI is defined by the Center for Medicare & Medicaid Services (CMS) as a “Hospital Harm” that requires monitoring and reporting, starting 2025.
Our goal: Eliminating Cardiac Surgery Associated-AKI (CSA-AKI)
A staggering 30% of patients suffer from AKI post-cardiac surgery. This results in extended hospital stays, higher mortality rates, and increased healthcare costs. Current protocols such as the KDIGO bundle are inadequate, and demonstrate almost no improvement in patient outcomes.
Kidney injury should not be collateral damage in cardiac surgery.
Kidney injury should not be collateral damage in cardiac surgery.
RenalProTM for CSA-AKI protection demonstrates a 52% reduction in AKI
RenalPro Therapy system uniquely balances IV fluid administration in response to the patient’s urine output in one ml increments which protects from AKI while preventing over- or under-hydration.
In a 220-patient randomized control UK study, RenalPro Therapy demonstrated a 52% reduction in AKI compared to standard care with no reported adverse events.
See how RenalProTM
protects the kidneys
Additional Applications
Contrast-Associated AKI (CA-AKI)
Contrast agents are commonly used in cath lab procedures. RenalPro therapy is designed to reduce the toxic effects that contrast agents can have on the kidneys. The efficacy and safety of RenalPro Therapy for prevention of CA-AKI were demonstrated in several EU clinical trials.
AKI in ICU Patients
AKI affects over 50% of ICU patients, driven by sepsis, infections, and nephrotoxic medications. CRS has initial results that demonstrate the potential for reduction of ICU related AKI based on the clinical principles for prevention of CSA-AKI and CA-AKI.
Get in Touch
please contact us a info@cardiorenalsystems.com if you have any question